April 15 (Reuters) - Neumora Therapeutics said on Monday the U.S. Food and Drug Administration had placed a clinical hold on early-stage study of its experimental schizophrenia drug. (Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.57 USD | -1.03% | -1.84% | -43.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.75% | 1.54B | |
+31.56% | 49.46B | |
+2.08% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.70% | 26.61B | |
-23.53% | 18.64B | |
+8.13% | 13.16B | |
+31.32% | 12.55B | |
+24.08% | 12.1B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- U.S. FDA places clinical hold on Neumora's schizophrenia drug study